Stem cells and tissue-specific cells can be grown in abundance from mature mammalian cells simply by blocking a certain membrane protein, according to scientists at the University of Pittsburgh School of Medicine and the National Institutes of Health (NIH). Their experiments, reported today in Scientific Reports, also show that the process doesn't require other kinds of cells or agents to artificially support cell growth and doesn't activate cancer genes.
Scientists hope that lab-grown stem cells and induced pluripotent stem (iPS) cells, which have the ability to produce specialized cells such as neurons and cardiac cells, could one day be used to treat diseases and repair damaged tissues, said co-author Jeffrey S. Isenberg, M.D., associate professor, Division of Pulmonary, Allergy and Critical Care Medicine, Pitt School of Medicine.
"Even though stem cells are able to self-renew, they are quite challenging to grow in the lab," he said. "Often you have to use feeder cells or introduce viral vectors to artificially create the conditions needed for these cells to survive and thrive."
In 2008, prior to joining Pitt, Dr. Isenberg was working in the National Cancer Institute (NCI) lab of senior author David D. Roberts, Ph.D., using agents that block a membrane protein called CD47 to explore their effects on blood vessels. He noticed that when cells from the lining of the lungs, called endothelium, had been treated with a CD47 blocker, they stayed healthy and maintained their growth and function for months.
Dr. Roberts' NIH team continued to experiment with CD47 blockade, focusing on defining the underlying molecular mechanisms that control cell growth.
They found that endothelial cells obtained from mice lacking CD47 multiplied readily and thrived in a culture dish, unlike those from control mice. Lead author Sukhbir Kaur, Ph.D., discovered that this resulted from increased expression of four genes that are regarded to be essential for formation of iPS cells. When placed into a defined growth medium, cells lacking CD47 spontaneously formed clusters characteristic of iPS cells. By then introducing various growth factors into the culture medium, these cells could be directed to become cells of other tissue types. Despite their vigorous growth, they didn't form tumors when injected into mice, a major disadvantage when using existing iPS cells.
"Stem cells prepared by this new procedure should be much safer to use in patients," Dr. Roberts noted. "Also, the technique opens up opportunities to treat various illnesses by injecting a drug that stimulates patients to make more of their own stem cells."
According to Dr. Isenberg, "These experiments indicate that we can take a primary human or other mammalian cell, even a mature adult cell, and by targeting CD47 turn on its pluripotent capability. We can get brain cells, liver cells, muscle cells and more. In the short term, they could be a boon for a variety of research questions in the lab."
In the future, blocking CD47 might make it possible to generate large numbers of healthy cells for therapies, such as alternatives to conventional bone marrow transplantation and complex tissue and organ bioengineering, he added.
"These exciting findings provide a rationale for using CD47 blocking therapies to increase stem cell uptake and survival in transplanted organs, matrix grafts, or other applications," said Mark Gladwin, M.D., professor and chief, Division of Pulmonary, Allergy and Critical Care Medicine, Pitt School of Medicine. "This continues a strong and productive collaboration between investigators at the NCI and the University of Pittsburgh's Vascular Medicine Institute."
Co-authors of the paper include David R. Soto-Pantoja, Ph.D., Michael L. Pendrak, Ph.D., Alina Nicolae, M.D., Ph.D., Zuqin Nie, Ph.D., and David Levens, M.D., Ph.D., of the National Cancer Institute (NCI); Erica V. Stein, B.S., M.Ed., of NCI and George Washington University; Chengyu Liu, Ph.D., of the National Heart, Lung and Blood Institute; Abdel G. Elkahloun, Ph.D., of the National Human Genome Research Institute (NHGRI); and Satya P. Singh, Ph.D., of the National Institute of Allergy and Infectious Diseases.
The project was funded by the NIH, NCI and NHGRI intramural programs and grants HL108954-01, HL103455-01, 11BGIA7210001; the Institute for Transfusion Medicine, the Western Pennsylvania Hemophilia Center, and Pitt's Vascular Medicine Institute.
About the University of Pittsburgh School of Medicine
As one of the nation's leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition. Driven mainly by the School of Medicine and its affiliates, Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1998. In rankings recently released by the National Science Foundation, Pitt ranked fifth among all American universities in total federal science and engineering research and development support.
Likewise, the School of Medicine is equally committed to advancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and to training highly skilled, compassionate clinicians and creative scientists well-equipped to engage in world-class research. The School of Medicine is the academic partner of UPMC, which has collaborated with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region's economy. For more information about the School of Medicine, see http://www.medschool.pitt.edu.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.